Sharps Technology, Inc. — Q1 2022 Form 10-Q
Filing identity: The supplied filing is for Sharps Technology, Inc. (NASDAQ: STSS, STSSW), not Skyai, Inc. It covers the three months ended March 31, 2022; the financial statements are unaudited.
Business context
Sharps is a pre-revenue medical-device company developing and seeking to commercialize patented safety syringes. It reported no revenue to date and had an accumulated deficit of $12.54 million at quarter-end. The company used a manufacturing facility in Hungary for product development and testing and expected to complete its acquisition of the facility by June 30, 2022.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 or prior date |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $506,375 | $467,564 |
| General and administrative expense | $830,909 | $447,576 |
| Operating loss | $1,337,284 | $915,140 |
| Net loss | $1,869,721 | $914,688 |
| Basic and diluted loss per share | $0.36 | $0.20 |
| Net cash used in operating activities | $1,216,051 | $716,071 |
| Cash at period-end | $255,615 | $1,479,166 at Dec. 31, 2021 |
There was no revenue or gross profit, so a gross margin is not meaningful. At March 31, total assets were $4.94 million, current liabilities were $3.31 million, and stockholders’ equity was $1.63 million. The company reported a $2.92 million working-capital deficit, versus $1.16 million at year-end 2021.
The December 2021 bridge notes had $2.0 million principal, bore 8% interest, and were secured by substantially all company assets. At March 31, notes payable were reported at $906,432 net of discount; the company also recorded $206,417 of discount accretion and $39,111 of interest expense. Contingent stock and warrant liabilities totaled $1.55 million.
Changes and unusual items
- Net loss roughly doubled year over year. G&A rose by about $383,000, reflecting higher payroll and consulting, stock compensation, marketing, professional fees, travel, and other costs.
- R&D increased by about $39,000. Higher facility operating costs and depreciation were partly offset by lower testing-material and stock-compensation costs.
- Other expense included a $287,000 fair-value charge on contingent stock and warrant liabilities, in addition to interest and debt-discount accretion.
- Operating cash use increased year over year. Investing cash use was $40,000, compared with $925,000 in Q1 2021; financing provided $32,500, versus $1.31 million in Q1 2021.
Outlook, risks, and subsequent events
Management expects R&D spending to rise as it develops and validates products, and says commercial inventory is needed to secure orders. The filing gives no quantified revenue or earnings guidance. It cautions that forward-looking plans are subject to risks and may differ materially from actual results.
After quarter-end, the company completed an IPO that generated approximately $14.2 million in net proceeds before certain listing and professional fees. It used proceeds to repay the $2.0 million notes and settled the contingent stock and warrant obligations by issuing 235,294 common shares and 235,294 warrants. The company also awarded 267,500 options after the IPO. These events are not reflected in the March 31 balance sheet.
Other matters to monitor include the proposed $2.5 million cash acquisition of the manufacturing facility, the outstanding $120,000 mold order, and a 2% royalty on related product sales. The company reported no material litigation or off-balance-sheet arrangements. Its 10-Q states it was not yet a public company and did not have disclosure controls and procedures as of March 31; it also identifies risks described in its IPO prospectus.
Important facts for investors to verify
- Confirm the filing entity: the document names Sharps Technology, Inc., despite the request metadata naming Skyai, Inc.
- Review the IPO’s final proceeds, offering costs, share and warrant dilution, and use of proceeds in subsequent filings.
- Assess post-IPO cash runway against operating burn, planned R&D, manufacturing, and inventory requirements.
- Verify the status, total cost, and closing conditions of the manufacturing-facility acquisition and mold purchase.
- Review the debt repayment and contingent-security settlement, including the resulting dilution and the effect of post-quarter option awards.